Viz.ai Named to Forbes AI 50 List of Top Artificial Intelligence Companies of 2023
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has been named to the 2023 Forbes AI 50 list of the most promising private artificial intelligence (AI) startups globally. This is the 4th time Viz.ai has been recognized in the Forbes AI 50 list.
“We are honored to be included in this year’s Forbes AI 50 list and proud that the Viz Platform is recognized globally for its unique value,” said Chris Mansi, CEO at Viz.ai. “By harnessing the power of AI, our platform addresses healthcare’s most pressing needs, helping to accelerate patient care by reducing systemic delays that stand between life-saving treatments and the individuals who need them.”
The Forbes AI 50 list is a preeminent recognition acknowledging the most transformative companies utilizing AI technology for the betterment of the business industry. In prior years, submissions were open to North America alone, but for the first time this year, the criteria was expanded to include startups globally with nearly 800 submissions in 2023.
The Viz Platform uses AI to detect disease earlier, unify care collaboration, and inform critical decisions to improve patient outcomes. Based on a patient’s suspected condition, the Viz Platform automatically alerts the care team to expedite a diagnosis and accelerate initiation of appropriate monitoring and treatment. Throughout the entire clinical workflow, from pre-hospital to post-acute care, healthcare providers can directly connect and assess high fidelity imaging and patient information in real-time. The Viz Platform offerings span neurology, vascular, cardiology, radiology and trauma.
To determine which companies that will be recognized on the AI 50 list, Forbes, in partnership with Sequoia Capital and Meritech Capital, commissions a panel of independent judges with deep expertise in the field of AI to assess notable determinants of each contender including, revenue, growth, valuation, talent on staff, and the strength of the company’s AI business application.
About Viz.ai, Inc.
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 220 million lives across 1,300+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients with a particular disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230412005559/en/
Contact information
Laurie Masonson
laurie.masonson@finnpartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
360Learning Integrates With UKG to Transform Enterprise Learning Experiences3.12.2025 15:00:00 EET | Press release
360Learning, the AI-powered collaborative learning platform that combines LMS and LXP capabilities to scale skills development for mid-size and enterprise companies, has announced the integration of its learning platform with UKG's industry-leading workforce operating platform. The partnership empowers companies to accelerate skills-based learning across every level of the organisation, from frontline employees to corporate teams and external partners. Through this integration, UKG Pro and UKG Ready customers can now leverage 360Learning’s comprehensive Learning Management System (LMS) and Learning Experience Platform (LXP) to address employee development and upskilling learning needs, as well as external training for customers and partners. With 360Learning, they’ll have access to the leading AI-powered content authoring tool, dramatically reducing course creation time. Benjamin Marchal, CEO at 360Learning, said: "Our integration with UKG makes it easier for organisations to connect l
Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides3.12.2025 15:00:00 EET | Press release
Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast cancer pathology slides. Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Identifying patients with germline BRCA1/2 mutations is essential for guiding targeted treatment decisions, but testing is not always consistently offered to eligible individuals, and implementation varies between countries. The model concept was initiated as part of Owkin’s ongoing partnership with Gustave Roussy and Centre Léon Bérard through PortrAIt, a French consortium dedicated to advancing precision medicine with AI-enabled digital pathology. Fostered through collaboration with AstraZeneca, as announced in October 2024, the development of BRCAura aims to accelerate and expand identification of BRCA mutations in patients with breast cancer. Strong validation across internationa
Winchester Interconnect Launches LiteSPEed ™ Cable: Faster, Lighter, Simpler Connectivity for Mission-Critical Systems3.12.2025 15:00:00 EET | Press release
Winchester Interconnect, an Aptiv company and leading supplier of high-performance interconnect solutions, today introduced LiteSPEed™ Cable, a next-generation single-pair Ethernet (SPE) solution that delivers 10-gigabit data rates in a dramatically smaller, lighter design. Built for the increasingly connected and space-constrained environments of aerospace, defense, industrial automation and next-generation mobility, LiteSPEed™ helps customers move more data with less cable, reducing weight, complexity, and cost while increasing system performance and reliability. “As systems become more intelligent and interconnected, engineers need lighter, more efficient ways to deliver power and data,” said Juan Contreres, director of product management. “LiteSPEed™ gives them a rugged, high-speed Ethernet solution that simplifies installation without compromising performance.” With advanced sensors, real-time analytics, and distributed control systems proliferating across industries, cabling has
Adva Network Security achieves BSI approval for PQC-encrypted edge networking device3.12.2025 15:00:00 EET | Press release
Adva Network Security today announced that the FSP 150-XG118Pro (CSH) 10Gbit/s edge device now delivers quantum-safe encryption based on post-quantum cryptography (PQC). This enhancement enables operators of critical network infrastructure (CNI) to secure data in motion and build future-ready networks. Certified by the German Federal Office for Information Security (BSI), the solution’s Ethernet encryption offers PQC crypto-agility via a software update, eliminating the need for hardware changes. With its new capabilities, the FSP 150-XG118Pro (CSH) is ideally suited for diverse high-security environments, ranging from national infrastructure to enterprise networks that require strict compliance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251203626212/en/ Adva Network Security’s technology is helping operators develop long-term strategies to keep critical network infrastructure safe and secure. “The threat of quantum com
Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing3.12.2025 15:00:00 EET | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President: Toshiaki Nagasato) today announced a strategic equity investment in Lyric Bio, Inc. (Head Office: San Carlos, USA, founded by Chief Executive Officer: Kayj Shannon and Chief Scientific Officer Melanie Matheu). Through this investment, Meiji Seika Pharma seeks to accelerate the early-stage development of Lyric Bio’s innovative platform for producing human immunoglobulin (IVIg), explore donation-independent manufacturing methods, and lay the groundwork for a more resilient, high-quality supply of plasma-derived therapeutics to meet increasing global demand. Lyric Bio is developing a next-generation biomanufacturing platform for IVIg production. The company’s approach uses tissue-mimicking bioreactors built on a proprietary laser-printed cellular substrate that enables ultra high-density cell growth and has the potential to deliver more than 1,000 IVIg doses from a single donor. This investment will accelerate Lyric Bio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom